Therapeutic Strategies in Cll with Curative Intent

Weiss, Mark A.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Research Project (R01)
• Project #: 5R01CA067823-02
• Application #: 2111611
• Study Section: Special Emphasis Panel (SRC (14))
• Project Start: 1995-08-01
• Project End: 1999-07-31
• Budget Start: 1996-08-01
• Budget End: 1997-07-31
• Support Year: 2
• Fiscal Year: 1996

Institution

• Name: Sloan-Kettering Institute for Cancer Research
• DUNS #: 064931884
• City: New York
• State: NY
• Country: United States
• Zip Code: 10065

Publications

Lamanna, Nicole; Jurcic, Joseph G; Noy, Ariela et al. (2009) Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 27:491-7

Noy, A; Verma, R; Glenn, M et al. (2001) Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. Blood 97:1929-36

Weiss, M A; Glenn, M; Maslak, P et al. (2000) Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia 14:1577-82

Konig, A; Schwartz, G K; Mohammad, R M et al. (1997) The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 90:4307-12